Experts Discuss AI's Future In Pharma

During a panel at the J.P. Morgan Health Conference, experts discussed the potential of artificial intelligence (AI) in improving clinical research in the pharmaceutical industry. The main goal of using AI in clinical research is to accelerate the development and delivery of new therapies to patients. AI can optimize trial design and management by leveraging historical clinical trial data to identify areas for improvement, leading to more efficient and informative trials.

Currently, AI is being used in three key ways: replacing humans in high-volume, repeatable processes, generating data-driven protocol drafts, and analyzing large volumes of data to find patterns and trends. However, there are risks associated with AI, including the technological preparedness of those working with AI and the quality of the data being fed into AI systems.

To see success with AI, companies need to attract and retain talented individuals capable of developing cutting-edge AI applications and focus on creating a good user experience. The panelists also expressed excitement about AI's potential in underserved areas like women's health and aging. While AI has the potential to revolutionize drug development, uncover what it will require to ensure positive outcomes.